当前位置: X-MOL 学术Lancet Oncol. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
miR-16: expanding the range of molecular targets in mesothelioma
The Lancet Oncology ( IF 51.1 ) Pub Date : 2017-09-01 , DOI: 10.1016/s1470-2045(17)30596-x
Dean Fennell

Malignant mesothelioma is a cancer caused by exposure to asbestos. It has a devastating prognosis, and its incidence has increased substantially in high-income countries during the past three decades. Systemic therapy comprising cisplatin and pemetrexed remains the only approved standard of care, a therapeutic plateau that has endured for more than 10 years. New, effective therapies based on an understanding of the underlying biology are clearly needed. By contrast with many other cancers, including lung cancer and melanoma, somatic mutations in oncogenic kinases have not been identified in the genomic landscape of mesotheliomas.

中文翻译:

miR-16:扩大间皮瘤的分子靶标范围

恶性间皮瘤是由接触石棉引起的癌症。它具有毁灭性的预后,并且在过去的三十年中,它的发生率在高收入国家中已大大增加。包含顺铂和培美曲塞的全身疗法仍然是唯一批准的护理标准,这种治疗平台已经持续了10多年。显然需要基于对潜在生物学的理解的新的有效疗法。与包括肺癌和黑色素瘤在内的许多其他癌症相比,在间皮瘤的基因组格局中尚未发现致癌激酶的体细胞突变。
更新日期:2017-09-04
down
wechat
bug